Danish pharmaceutical firm Novo Nordisk has agreed to buy three drug manufacturing sites belonging to US firm Catalent for an upfront payment of $11 billion. The deal involved the acquisition of Catalent by Novo Holdings, the Danish firm’s holding company. The three Catalent manufacturing sites sold to Novo Nordisk are specialized in the sterile filling of drugs and located in Italy, Belgium and Indiana, US. The sites employ more than 3,000 people. The acquisition is projected to have a low single-digit negative impact on Novo Nordisk’s operating profit growth in both 2024 and 2025. “The agree…